Instrumento Inactivo

Acciones Cubist Pharmaceuticals Inc

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	13/01/15
Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen	21/12/14
Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées	20/12/14
Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	20/12/14
Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	10/12/14

Directores	Puesto	Edad	Desde
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/97

Administradores	Puesto	Edad	Desde
Martin Hermanus Soeters BRD	Director/Board Member	70	01/09/06
Kenneth J. Martin BRD	Director/Board Member	70	25/09/13

Sector

	Varia. 1 de ene.	Capi.
CSL LIMITED	+3,91 %	94,74 mil M
SAMSUNG BIOLOGICS CO.,LTD.	-3,68 %	37,28 mil M
BIOGEN INC.	-11,61 %	32,68 mil M
UCB	+74,21 %	27,72 mil M
BIOMARIN PHARMACEUTICAL INC.	-13,40 %	16,19 mil M
INCYTE CORPORATION	-2,29 %	13,88 mil M
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12,21 %	11,58 mil M
ALTEOGEN INC.	+188,83 %	10,92 mil M
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-53,94 %	9540,9 M